Core Viewpoint - MicroPort CardioFlow-B (02160) has seen a significant stock increase, with a rise of over 10% and a current price of 1.25 HKD, reflecting strong market interest and positive developments in the company's product offerings [1] Group 1: Product Development and Market Expansion - The VitaFow series transcatheter aortic valves and delivery systems have been introduced in 35 countries, with nearly 1,300 implants to date [1] - The projected implant volume for 2025 is expected to exceed 850 cases, representing a nearly 350% increase compared to 2024 [1] - The second half of 2025 is anticipated to see over 170% growth in implant volume compared to the first half [1] Group 2: Strategic Developments - On December 21, the company announced a strategic merger with MicroPort Cardiac Rhythm Management, which is expected to enhance the company's resilience against risks by diversifying beyond a single market segment [1] - The merger will provide access to a more mature global sales network, facilitating accelerated expansion into overseas markets [1] - The collaboration aims to leverage both companies' research and development capabilities in medical devices to create a global platform for heart failure treatment [1]

Core Viewpoint - Micron Heart Technology-B (02160.HK) has reported significant growth in the adoption of its VitaFow® series transcatheter aortic valves and delivery systems (TAVI), with a projected increase in implant volume for 2025 [1] Group 1: Product Performance - The VitaFow® series TAVI has been introduced in 35 countries and regions globally, with a cumulative implant volume nearing 1,300 cases [1] - The implant volume for 2025 is expected to exceed 850 cases, representing a nearly 350% increase compared to 2024 [1] - In the second half of 2025, the implant volume is anticipated to grow by over 170% compared to the first half, driven by the commercialization of VitaFow Liberty® following CE certification in European countries [1] Group 2: Market Expansion - The company is focusing on expanding its market share in emerging markets in Asia and Latin America, contributing to the anticipated growth in implant volumes [1]

Core Viewpoint - The company, HeartLink Medical-B (02160.HK), has announced significant growth in its VitaFow® series of transcatheter aortic valves and delivery systems (TAVI), with a cumulative implantation of nearly 1,300 cases across 35 countries and regions as of the announcement date [1] Group 1: Market Expansion - The projected implantation volume for 2025 is expected to exceed 850 cases, representing an increase of nearly 350% compared to 2024 [1] - In the second half of 2025, the implantation volume is anticipated to grow by over 170% compared to the first half, driven by the commercialization of VitaFowLiberty® following CE mark approval in European countries and continued market share growth in emerging markets in Asia and Latin America [1] Group 2: Strategic Enhancements - The company's board believes that the recent acquisition of Micro-Invasive Cardiac Management will strengthen local channel resources and clinical support systems in mature markets like Europe, significantly improving market access efficiency for TAVI products [1] - The company aims to continuously leverage the synergies from business integration, advance the research and clinical progress of next-generation TAVI products, and enhance its overall competitiveness in the global valve treatment sector [1]

Core Insights - The early feasibility study results for the AltaValve™ transcatheter mitral valve replacement (TMVR) device developed by 4C Medical Technologies, Inc. have been published, showing promising outcomes for high-risk patients with symptomatic severe mitral regurgitation (MR) [1] Group 1: Study Results - The study included 30 high-risk patients across Europe, the United States, and Japan, with 13 patients undergoing the transapical approach and 17 patients undergoing the transseptal approach [1] - The procedural success rate was reported at 97%, with complete elimination of MR in all patients [1] - The mean transvalvular pressure gradient decreased from 2.5 mmHg at baseline to 2.1 mmHg post-procedure, indicating significant improvement in cardiac hemodynamics [1] - 96% of patients improved to NYHA functional class I-II after one year, reflecting a substantial enhancement in quality of life [1] Group 2: Safety and Mortality - The one-year all-cause mortality rate was 17% for the transapical group and only 7% for the transseptal group, with no cases of cardiac-related mortality [1] - There were no adverse events such as stroke, new-onset atrial fibrillation, or re-intervention on the mitral valve reported in the entire cohort [1] Group 3: Regulatory Approval - AltaValve™ received two breakthrough device designations from the FDA in 2024 and is currently conducting pivotal clinical studies in Europe and the United States under an FDA-approved Investigational Device Exemption (IDE) [2]

Core Insights - The early feasibility study results for the AltaValveTM transcatheter mitral valve replacement (TMVR) device developed by 4C Medical Technologies, Inc. have been published, showing promising outcomes in high-risk patients with symptomatic severe mitral regurgitation (MR) [1][2] Group 1: Study Results - The study included 30 patients across Europe, the United States, and Japan, all of whom were at high surgical risk and had symptomatic severe MR [1] - The technical success rate of the procedure was reported at 97%, with complete elimination of MR in all patients [1] - The mean transvalvular pressure gradient decreased from 2.5 mmHg at baseline to 2.1 mmHg post-procedure, indicating significant improvement in cardiac hemodynamics [1] Group 2: Safety and Outcomes - The one-year all-cause mortality rate was 17% for the transapical group and only 7% for the transseptal group, with no cases of cardiac-related mortality [1] - There were no adverse events such as stroke, new-onset atrial fibrillation, or re-intervention on the mitral valve reported in the entire cohort [1] - 96% of patients improved to NYHA functional class I-II at one year, reflecting a substantial enhancement in quality of life [1] Group 3: Regulatory Status - AltaValveTM has received two breakthrough device designations from the FDA in 2024 and is currently undergoing pivotal clinical studies in Europe and the United States under an FDA-approved Investigational Device Exemption (IDE) [2]

Core Viewpoint - MicroPort CardioFlow-B (02160) has announced significant growth in its VitaFow® transcatheter aortic valve and delivery system, with a cumulative implantation of nearly 1,300 cases across 35 countries and regions as of the announcement date [1] Group 1: Market Expansion - The company expects the implantation volume to exceed 850 cases in 2025, representing an increase of nearly 350% compared to 2024 [1] - In the second half of 2025, the implantation volume is projected to grow by over 170% compared to the first half, driven by the commercialization of VitaFow Liberty® in European countries following CE certification and increased market share in emerging markets in Asia and Latin America [1] Group 2: Strategic Development - The board believes that the recent acquisition of MicroPort Cardiac Rhythm Management will enhance local channel resources and clinical support systems in mature markets like Europe, significantly improving market access efficiency for TAVI products [1] - The company aims to continuously leverage the synergies from business integration, advancing the research and clinical progress of next-generation TAVI products, and enhancing its comprehensive competitiveness in the global valve treatment field [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 本公告乃由微創心通醫療科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願作出，以知會本公司股東及潛在投資者有關本集團最新業務進展。 本公司董事「( 董 事」)會（「董事會」）欣 然 宣 佈， 截 至 本 公 告 之 日， 本 集 團 VitaFow®系列經導管主動脈瓣膜及輸送系統（「TAVI」）已進入全球35個國家及地 區，累計植入量近1,300例。其中，2025年植入量預計將超過850例，較2024年增 長近350%。2025年下半年，得益於VitaFow Liberty®獲得CE證後在歐洲國家商業 化的持續拓展，以及在亞洲和拉美新興市場國家份額的持續提升，植入量較上 半年增長超過170%。 – 1 – 本公司董事會相信，通過近期完成的併購微創心律管理的交易，本集團將進一 步強化在歐洲等成熟市場的本地化渠道資源與臨床支持體系，顯著提升TAVI 產品的新市場准入效率與既有市場的滲透深度。未來 ...

（ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 自願公告 AltaValveTM早期可行性研究一年隨訪結果正式公佈 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 本公告乃由微創心通醫療科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願作出，以知會本公司股東及潛在投資者有關本集團最新業務進展。 本 公 司 董 事（「董 事」）會（「董事會」）欣 然 宣 佈，近 日，由 集 團 聯 營 公 司 4C Medical Technologies, Inc.（「4C Medical」）自主研發的AltaValveTM經導管二尖瓣置 換（「TMVR」）醫療器械（「AltaValveTM」）的早期可行性研究一年隨訪結果正式公 佈。 本次研究覆蓋歐洲、美國、日本多中心，納入患者30名，均為手術高風險、 伴有 ...

每经AI快讯，微创心通-B(02160.HK)盘中一度涨超9%，截至发稿涨6.06%，报1.05港元，成交额448.37 万港元。 ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of MicroPort Cardiac Rhythm Management (02160), which rose over 9% during trading and is currently up 6.06% at HKD 1.05, with a trading volume of HKD 4.48 million [1] - MicroPort's VitaFlow Liberty aortic valve and retrieval system has received approval for sale in Morocco, marking its first entry into the African market, which is heavily reliant on imported medical devices [1] - The acquisition of Cardiac Rhythm by MicroPort Medical has been finalized, which will enhance the integration of its structural heart disease and cardiac rhythm management business segments, accelerating the development of a comprehensive device management solution for heart failure [1]